Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12 USD | -4.15% | -0.17% | -47.77% |
08/05 | Baird Adjusts Price Target on EyePoint Pharmaceuticals to $38 From $46, Keeps Outperform Rating | MT |
08/05 | Earnings Flash (EYPT) EYEPOINT PHARMACEUTICALS Posts Q1 Revenue $11.7M | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.77% | 65Cr | |
+32.35% | 69TCr | |
+29.39% | 59TCr | |
-1.55% | 37TCr | |
+20.12% | 33TCr | |
+7.21% | 29TCr | |
+14.25% | 24TCr | |
-3.03% | 21TCr | |
+10.02% | 21TCr | |
+8.60% | 17TCr |
- Stock Market
- Equities
- EYPT Stock
- News EyePoint Pharmaceuticals, Inc.
- Eyepoint Pharmaceuticals Insider Sold Shares Worth $484,124, According to a Recent SEC Filing